CoChat

Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer

Open access

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

Significance: The survival benefit of antiangiogenic therapies for cancer patients has been limited, potentially due to intrinsic/acquired resistance. Deciphering and targeting resistance mechanisms are critical to improving treatment outcome, especially in cancers where antiangiogenic therapies are standard of care, such as colorectal cancer (CRC). Consistent with our clinical findings, we found up-regulation of CXCL12/CXCR4 in orthotopic CRC models and conditional Apc mutant spontaneous rectal tumors after anti-VEGFR2 treatment. CXCR4 signaling recruited immunosuppressive innate immune cells such as Ly6C low monocytes and Ly6G + neutrophils to the CRCs, conferring resistance to VEGFR2 blockade. Furthermore, we successfully targeted these pathways genetically and pharmacologically, including with an FDA-approved agent Plerixafor (AMD3100), which significantly enhanced treatment response. These strategies have the potential for rapid clinical translation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1710754114

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 150

Metadata

Authors
Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., Kim, J. K., Clark, J. W., Willett, C. G., Yun, S. H., Luster, A. D., Padera, T. P., Jain, R. K., & Fukumura, D.
Affiliations
  • Harvard University (US)
  • Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114;
  • Duke Medical Center (US)
Venue
Proceedings of the National Academy of Sciences
Published
2017-09-12
Volume
114
Issue
39
Pages
10455-10460
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2754366826
Cited by
138
References
57
Citations by year
2026: 10 · 2025: 12 · 2024: 15 · 2023: 17 · 2022: 18 · 2021: 23 · 2020: 19 · 2019: 15 · 2018: 9
FWCI
4.91
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • HHS | NIH | National Cancer Institute (P01-CA080124, R01-CA126642, R35-CA197743, CA096915)
  • HHS | National Institutes of Health (DP2 OD008780, R00 CA137167)
  • DOD | U.S. Army (W81XWH-10-1-0016)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
colorectal cancer, anti-angiogenic therapy, CXCR4, CXCL12, neutrophils, immunosuppression, treatment resistance, plerixafor, tumor microenvironment, innate immune cells
MeSH terms
Bevacizumab, Cyclams, Ramucirumab, Animals, Antibodies, Monoclonal, Antigens, Ly, Benzylamines, Heterocyclic Compounds, Mice, Inbred C57BL, Monocytes, Neutrophils, Tumor Cells, Cultured, Colorectal Neoplasms, Mice, Knockout, Receptors, CXCR4, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor A, Cell Proliferation, Mice, Chemokine CXCL12, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.